These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 36739367

  • 1. Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
    Lichtenstein GR, Cohen BL, Salese L, Modesto I, Wang W, Chan G, Ahmed HM, Su C, Peyrin-Biroulet L.
    Dig Dis Sci; 2023 Jun; 68(6):2624-2634. PubMed ID: 36739367
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
    Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE.
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):591-601.e8. PubMed ID: 33684552
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL, Vermeire S, Long MD, Panés J, Ng SC, Kulisek N, Mundayat R, Lawendy N, Vranic I, Modesto I, Su C, Melmed GY.
    Inflamm Bowel Dis; 2023 Jan 05; 29(1):85-96. PubMed ID: 35648151
    [Abstract] [Full Text] [Related]

  • 6. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C.
    Inflamm Bowel Dis; 2018 Sep 15; 24(10):2258-2265. PubMed ID: 29850873
    [Abstract] [Full Text] [Related]

  • 7. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
    Winthrop KL, Loftus EV, Baumgart DC, Reinisch W, Nduaka CI, Lawendy N, Chan G, Mundayat R, Friedman GS, Salese L, Thorpe AJ, Su C.
    J Crohns Colitis; 2021 Jun 22; 15(6):914-929. PubMed ID: 33245746
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
    Panés J, D'Haens GR, Sands BE, Ng SC, Lawendy N, Kulisek N, Guo X, Wu J, Vranic I, Panaccione R, Vermeire S.
    United European Gastroenterol J; 2024 Jul 22; 12(6):793-801. PubMed ID: 38778549
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
    Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE.
    Clin Gastroenterol Hepatol; 2022 Aug 22; 20(8):1821-1830.e3. PubMed ID: 33127596
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W, Study A3921063 Investigators.
    N Engl J Med; 2012 Aug 16; 367(7):616-24. PubMed ID: 22894574
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
    Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C.
    Clin Gastroenterol Hepatol; 2019 Jan 16; 17(1):139-147. PubMed ID: 30012431
    [Abstract] [Full Text] [Related]

  • 16. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Sandborn WJ, Armuzzi A, Liguori G, Irving PM, Sharara AI, Mundayat R, Lawendy N, Woolcott JC, Danese S.
    Inflamm Bowel Dis; 2022 Sep 01; 28(9):1338-1347. PubMed ID: 34958359
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
    Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR.
    Inflamm Bowel Dis; 2021 Aug 19; 27(9):1394-1408. PubMed ID: 33324993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.